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Background: The effectiveness of an erbium-doped: yttrium, aluminum and garnet (Er: YAG) laser (EYL) for the 
treatment of peri-implant disease (PID) remains unclear. The aim of this study was to compare non-surgical EYL 
therapy for PID with locally delivered minocycline hydrochloride (MC) ointment therapy by evaluating clinical, 
microbiological, and biochemical markers.
Methods: Thirty-seven patients with PID were randomly assigned to either the EYL group (n = 18) or the MC group 
(n = 19). The clinical, microbiological, and biochemical markers at baseline and at 1 and 3 months after treatment 
were compared between the two groups. Subgingival plaque and peri-implant crevicular fluid (PICF) were collec-
ted from the diseased pockets.
Results: In the EYL group, probing pocket depth (PPD) was significantly decreased after treatment when compa-
red with baseline. On the other hand, in the MC group, there was no significant decrease in PPD after treatment. 
Specific bacteria associated with PID were not determined. The counts of both Gram-positive and -negative species 
did not significantly decrease in the EYL group at 3 months after treatment. In the MC group, the counts of almost 
all bacterial species were significantly decreased after treatment. Biochemical marker analysis of PICF revealed 
significantly lower levels of metalloproteinase (MMP)-9 in the EYL group, as compared with the MC group at 3 
months after treatment (p= 0.009). 
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Introduction
Dental implants are commonly used as oral prostheses 
after the loss of natural teeth to improve oral health of 
patients. However, dental implants are known to cause 
peri-implant disease (PID), which is classified as pe-
ri-implant mucositis, an inflammatory disease restricted 
to the area within the oral mucosa surrounding a dental 
implant, or peri-implantitis (PI), which is characterized 
by the loss of implant-supporting bone (1). PID is cau-
sed by the interaction between peri-implant microbiota 
and host immune responses. PI causes lesions that may 
display more severe characteristics and progress more 
rapidly than periodontitis (2). The prevalence of PID is 
increasing; thus, prevention and treatments for PID are 
important issues for dentists (3). Clinical and radiogra-
phic parameters, such as probing pocket depth (PPD), 
clinical attachment level (CAL), concomitant bleeding 
on probing (BOP), suppuration, mobility (Mo), and 
bone loss (BL), are widely used for diagnosis of PID (4). 
Many studies focusing on microbiological and bioche-
mical marker analyses have been reported. The specific 
microbiota associated with PID, and the similarities or 
differences between the etiologies of peri-implant and 
periodontal diseases remain to be clarified. Kumar et al. 
reported less diversity in PI as compared with periodon-
titis (5), whereas, Koyanagi et al. demonstrated more di-
versity in PI (6). In addition, biomarkers associated with 
PID in peri-implant crevicular fluid (PICF) have also 
been widely studied (7,8). A recent review article found 
that higher levels of pro-inflammatory cytokines in the 
PICF may be associated with PI (9). However, inconsis-
tent results have led to the conclusion that PICF analysis 
is not yet sufficient for the diagnosis of PID (4,10).
The effectiveness of methods used for the treatment 
of PID has been unpredictable (1). As a non-surgical 
treatment, conventional mechanical debridement mo-
notherapy has limited efficacy (11,12); thus, adjunctive 
therapies to mechanical debridement, such as locally de-
livered antibiotics and alternative therapies, have been 
employed (13). Among these therapies, erbium-doped: 
yttrium, aluminum and garnet (Er: YAG) laser (EYL) 
therapy has recently received considerable attention for 
its unique and specific effects on the decontamination 
of debris from the infected implant surface without me-
chanical or thermal side effects (14). Recently, the cli-
nical effectiveness of non-surgical EYL therapy for PI 
was summarized in a review article and meta-analysis 
(13,15). However, to our knowledge, changes in micro-
Conclusions: Non-surgical therapy with an EYL for PID was clinically effective, with decreased MMP-9 levels in 
PICF, which may lead to reduced peri-implant tissue destruction.
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biota and biochemical markers following EYL treatment 
have not been studied. 
Therefore, we aimed to elucidate the effectiveness of 
non-surgical EYL therapy for PID by comprehensive 




Patients who were referred to the periodontal clinics of 
Niigata University Medical and Dental Hospital (Nii-
gata, Japan), Asahi University (Gifu, Japan), or Osaka 
Dental University (Osaka, Japan) between January 2013 
and August 2014 were recruited for participation in this 
study. All patients were Japanese, systemically healthy, 
and had been receiving regular supportive periodontal 
therapy (SPT) at one of the three institutes. Patients 
were diagnosed as having PID following treatment of 
one infected dental implant, which was identified as the 
most severe with a PPD greater than 5 mm and conco-
mitant BOP from at least two sites. Patients who met 
any of the following exclusion criteria, as reported in a 
standard questionnaire, were excluded from analysis: 1) 
systemic illness or medical condition; 2) pregnancy; 3) 
use of immunosuppressive drugs, systemic antibiotics, 
or anti-inflammatory drugs in the 3 months prior to the 
experiment; 4) previous history of surgical or non-surgi-
cal therapy for periodontitis or PID, within 6 or 3 mon-
ths prior to the experiment, respectively; 5) acute perio-
dontal burden on the infected implant and the adjacent 
natural tooth; and 6) pacemaker or any other systemic 
condition that might be affected by EYL treatment.
-Sample size calculation
An appropriate sample size was calculated before ini-
tiation of the study. According to Cohen’s suggestion, 
setting the effect size = 0.80, alpha = 0.05, and power at 
80%, the sample size was determined as 19 subjects per 
group. Thus, 20 subjects per group were recruited.
Study design
The study protocol was approved by the regional ethics 
committees of each of the three institutes and all subjects 
submitted signed consent forms prior to participation.
A total of 40 patients were randomly assigned a code 
number, which was used to identify the subjects throu-
ghout the study, and were then assigned to either the 
EYL group (n=20) or the minocycline hydrochloride 
(MC) ointment local delivery group (n=20). At baseline, 
before treatment, periodontal examination of the resi-
J Clin Exp Dent. 2018;10(10):e970-8.                                                                                                                                                        Er: YAG laser therapy for peri-implant disease
e972
dual natural teeth and infected implants was performed. 
Subgingival plaque and PICF were collected from the 
first and second deepest pocket sites of the infected im-
plant for microbiological and biomarker analyses, res-
pectively. After 1 to 4 weeks, either EYL irradiation or 
local administration of MC ointment was applied to the 
peri-implant diseased pockets. The clinical, microbiolo-
gical, and biochemical markers were re-evaluated at 1 
and 3 months after treatment. During the study period, 
the subjects did not use any medications or undergo pe-
riodontal treatments to adhere to the study protocol.
-Assessment of clinical parameters
Three standardized examiners (YK, TY and TT) asses-
sed the clinical parameters. All patients underwent cli-
nical and radiographical examinations at the first visit. 
Information regarding smoking habits, systemic health, 
and use of medications was obtained from all patients. 
The following clinical measurements were assessed in 
both full mouth residual natural teeth and infected im-
plants: PPD, CAL, BOP, Mo, and BL. PPD, CAL and 
BOP were recorded at six sites per tooth using a ma-
nual periodontal probe (CP-12 Color-Coded Probe, Hu-
Friedy, Chicago, IL, USA) for the natural teeth and a 
disposable manual pocket contact probe (Nippon Shi-
ken Dental Co., Ltd., Tokyo, Japan) for the infected im-
plants. CAL was defined as the area extending from the 
shoulder to the bottom of the implant pocket.
-Biochemical marker analysis
PICF samples were collected before subgingival pla-
que samples. PICF collection and biochemical marker 
analysis were performed as described in our previous 
report (16). Supernatants of the eluates were stored at 
-80°C and were then sent to Filgen Inc. (Nagoya, Japan) 
for biochemical marker analysis. Levels of Interleukin 
(IL)-1α, IL-1β, IL-6, IL-8, tumor necrosis factor (TN-
F)-α, and metalloproteinase (MMP)-1, 3, 9, and 13 were 
determined with a multiplex suspension array system, 
whereas C-reactive protein (CRP) levels were deter-
mined using a commercially available enzyme-linked 
immunosorbent assay (Quantikine® ELISA, R&D sys-
tems, Minneapolis, MN, USA).
-Microbiological analysis
Subgingival microbial samples were quantitatively 
analyzed by the polymerase chain reaction (PCR)-invader 
method by BML Corporation (Saitama, Japan) (17). After 
analysis, remaining microbiological samples were sent to 
Techno-Suruga Laboratory Co., Ltd. (Shizuoka, Japan) for 
comprehensive terminal restriction fragment length poly-
morphism (T-RFLP) analysis (18). The HhaI and MspI res-
triction enzymes were used to digest PCR products.
-Treatment of PID
The EYL irradiation method was standardized before 
the start of this study and all treatments were performed 
by the same three aforementioned well-trained doctors 
from each of the three institutes in order to avoid bias.
-Er: YAG laser treatment
An EYL (Arwin Adverl Evo, J. Morita Mfg. Corp., Kyo-
to, Japan) with an optical fiber delivery and contact tip 
system was used. Laser parameters were set at an energy 
level of 30 mJ/ 25 pps (panel display) using irrigation 
with distilled water at a rate of 5-7 mL/min in accor-
dance with the manufacturer’s instructions. An air-water 
mixture was released coaxially through the contact tip 
to cover the entire target area during irradiation using a 
tapered tip made of fused quartz (model no. PS600T). A 
new tip was used for each patient. Irradiation was dis-
persed from the coronal to the apical region in parallel 
paths with inclination of the tip (approximately 15–30° 
to the implant surface) in a sweeping motion at a rate of 
1 mm/s. Furthermore, the treatment was implemented 
as a monotherapy without ultrasonic scaling under local 
anesthesia with 2% lidocaine (+ 1:80,000 epinephrine).
-Locally delivered MC ointment treatment
In the MC group, the peri-implant pocket was irrigated 
with 2 mL of sterile distilled water (Otsuka Pharmaceu-
tical Co., Ltd., Tokyo, Japan) using a 3-mL disposable 
syringe (Nipro Medical Corporation, Osaka, Japan) and 
a plastic washing needle (Neo Dental Chemical Products 
Co., Ltd., Tokyo, Japan). Then, subjects received local 
delivery of 2% MC ointment (Periocline®; Sunstar Inc., 
Osaka, Japan) to the peri-implant pocket.
-Statistical analyses
Intergroup comparisons at baseline between the EYL 
and the MC groups regarding age and the clinical pa-
rameters of the residual natural teeth and the infected 
implants were performed using Student’s t-test, with 
the exception of the BOP-positive infected implants. In 
addition, Chi-squared test was used for comparisons of 
male/female ratio, number of smokers, and proportion 
of BOP-positive infected implants at baseline between 
the two groups. Moreover, Mann–Whitney U-test was 
used for comparisons of the types of subgingival orga-
nisms and biomarkers in PICF between the two groups. 
Intragroup comparisons between baseline and re-exami-
nation measurements of PPD and CAL in the infected 
implants were performed using paired t-test, while the 
proportions of BOP-positive infected implants were 
compared using the McNemar’s test. In addition, com-
parisons of the subgingival microorganisms and biomar-
kers in PICF between the two groups were performed 
using the Wilcoxon’s signed-rank test. All tests for intra-
group comparisons were adjusted with Bonferroni’s co-
rrection. SPSS ver. 21.0 software (IBM, Tokyo, Japan) 
was used for all statistical analyses, and the significance 
level was set at 5%.
Results
Three (EYL group, 2; MC group, 1) of 40 patients dro-
pped out during the study period. A total of 37 patients 
were finally included for analysis (Table 1).
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Laser group (N=18) Minocycline group (N=19)
Baseline 1 month 3 months Baseline 1 month 3 months
Age (years) 64.1±8.5 64.8±7.2
Male/female 6/12 9/10
Number of subjects who 
smoke
1/18 2/19
Number of teeth present 20.4±3.6 20.1±6.2
mean PPD (mm) 2.2±0.7 2.3±0.5
mean CAL (mm) 2.6±0.8 2.7±0.7
BOP (% positive) 20.7±18.8 14.6±13.3
Clinical characteristics-measured sites for subgingival plaque with peri-implantitis
PPD (mm) 6.6±1.4 5.8±1.7* 6.0±1.7** 6.1±1.2 5.7±1.7 5.7±2.0
CAL (mm) 6.9±1.5 6.4±1.8 6.4±1.9 6.3±1.7 6.1±1.8 6.2±2.0
BOP (% positive) 94.4 72.2 66.7 84.2 68.4 63.2
BL (%) 29.9±20.5 19.2±21.1
Table 1: Demographic and clinical characteristics of the study population.
Values represent mean ± standard deviation 
*Statistically significant change from baseline to 1 month (p= 0.002).
**Statistically significant change from baseline to 3 months (p= 0.007).
-Clinical parameters
The demographics and clinical characteristics of the 
study patients are illustrated in table 1. There were no 
statistically significant differences in any of the baseline 
clinical parameters between the two groups with regard 
to the periodontal status of the residual natural teeth or 
the infected implants (p > 0.05).
Intragroup comparisons showed that the mean PPD of 
the infected implants had significantly decreased at 1 
and 3 months after treatment in the EYL group, as com-
pared with baseline values (p = 0.002 and 0.007, respec-
tively). On the other hand, in the MC group, there were 
no significant differences in the mean PPD of the infec-
ted implants from the baseline values to 1 and 3 months 
after treatment. CAL and the percentage of BOP-positi-
ve sites of the infected implants were not significantly 
different between baseline observations and those obtai-
ned at 1 and 3 months after treatment in both groups (p 
> 0.025).
-Microbiological evaluation of peri-implant pocket
PCR-invader analysis
Intragroup comparisons revealed no significant differen-
ces in subgingival bacterial counts after treatment when 
compared with baseline observations in both groups (p 
> 0.05). In addition, intergroup comparisons of the total 
and periodontal subgingival bacteria between the two 
groups demonstrated no significant differences at baseli-
ne vs. 1 and 3 months after treatment (p  > 0.05) (Table 
2).
T-RFLP analysis
The effects of the two PID treatment methods were com-
pared by dividing the bacteria into Gram-negative (Fig. 
1,2) and Gram-positive species (Fig. 3). Intragroup com-
parisons showed no significant differences in the counts 
of Gram-negative (Fig. 2) and Gram-positive (Fig. 3) 
species between baseline observations and those at 1 and 
3 months after treatment in the EYL group; however, the 
counts of Porphyromonas and Prevotella species, which 
were digested with HhaI were significantly lower after 
1 month when compared with baseline observation (p = 
0.015; Fig. 1).
On the other hand, in the MC group, the counts of Por-
phyromonas and Prevotella species were significantly 
decreased at 1 (p = 0.011 and 0.004, respectively) and 3 
months (p = 0.006, and 0.002, respectively) after treat-
ment, as compared with baseline values (Fig. 1). In ad-
dition, Porphyromonas, Prevotella, Fusobacterium, and 
Neisseria were significantly decreased at only 1 month 
after treatment, as compared with baseline values (p = 
0.008; Fig. 2). Porphyromonas, Prevotella, and Fuso-
bacterium were also significantly decreased after 1 and 
3 months when compared with those at baseline (p = 
0.014, p = 0.015, respectively; Fig. 2). Moreover, Strep-
tococcus, Eubacterium Filfactor, and Parvimonas were 
significantly decreased after 1 and 3 months when com-
pared with those at baseline (p < 0.016; Fig. 3).
Biochemical analysis in PICF from PID pockets
Biochemical analysis was performed using 111 PICF 
samples collected from 37 patients at three time-points 
(baseline and 1 and 3 months after treatment). Three of 
the 10 biochemical markers (IL-1α, IL-8, and MMP-13) 
were completely detectable within the range of the as-
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Baseline 1 month 3 months
Laser group Total bacteria 4.8±0.2 4.7±0.1 4.8±0.1
(N=18) P. intermedia 1.1±0.2 1.2±0.3 1.3±0.3
P. gingivalis 1.9±0.4 1.9±0.3 1.8±0.3
T. forsythia 2.7±0.2 2.2±0.3 3.0±0.3
T. denticola 1.7±0.3 1.5±0.3 1.7±0.3
F. nucleatum 3.3±0.2 3.0±0.2 3.3±0.1
Minoycline group Total bacteria 5.0±0.1 4.7±0.1 4.6±0.2
(N=19) P. intermedia 1.5±0.3 1.1±0.2 1.2±0.3
P. gingivalis 2.0±0.3 1.2±0.2 1.5±0.3
T. forsythia 3.1±0.2 2.6±0.2 2.7±0.2
T. denticola 1.6±0.3 1.5±0.3 1.4±0.2
F. nucleatum 3.3±0.1 3.2±0.1 3.0±0.2
Table 2: Subgingival bacterial counts in each group.
Values represent mean ± standard error (log10/ml). 
P. intermedia, Prevotella intermedia; P. gingivalis, Porphyromonas gingivalis; T. forsythia, Tannerella forsythia; T.denticola, 
Treponema denticola; F.nucleatum, Fusobacterium nucleatum.
Fig. 1: Bacterial counts (log10/mL) of Porphyromonas and Prevotella species (upper and lower box-plots) in each group at 
baseline and at 1 and 3 months after therapy. Upper and lower box-plots shows bacterial species treated with the HhaI and 
MspI restriction enzymes, respectively. Diagrams represent the medians and the 25 and 75 percentiles as boxes, the 10 and 90 
percentiles as whiskers, and the outliers as circles (O). 
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Fig. 2: Bacterial counts (log10) of Porphyromonas, Prevotella, Fusobacterium, and Neisseria species (up-
per box-plots), and Porphyromonas, Prevotella, and Fusobacterium species (lower box-plots) in each group 
at baseline and at 1 and 3 months after therapy.
Fig. 3: Bacterial counts (log10) of Streptococcus, Eubacterium, Filfactor, and Parvimonas species (both 
upper and lower box plots) in each group at baseline and at 1 and 3 months after therapy.
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say, whereas 6 markers were partially below the lower 
limit of detection. On the other hand, MMP-9 levels were 
partially greater than the detection limit. Thus, for the sta-
tistical analysis, zero and the maximum value within the 
Laser group (N=18)
Baseline 1 month 3 months
median max/ min median max/ min median max/ min
IL-1a (ng/ml) 5.05 14.65/ 0.41 3.90 14.48/ 0.29 4.46 12.22/ 0.04
IL-1b (ng/ml) 0.10 11.9/ 0.00 0.12 8.71/ 0.00 0.05 1.25/ 0.00
IL-6 (pg/ml) 0.93 35.25/ 0.00 0.61 17.05/ 0.00 0.66 10.46/ 0.00
IL-8 (ng/ml) 0.38 4.39/ 0.04 0.24 2.12/ 0.01 0.36 1.29/ 0.01
TNF-a (pg/ml) 6.16* 25.43/ 1.18 4.34 50.31/ 0.64 4.32 20.82/ 0.44
CRP (ng/ml) 0.35 0.55/ 0.11 0.31 1.51/ 0.10 0.34 1.21/ 0.11
MMP-1 (ng/ml) 0.09 5.09/ 0.002 0.07 0.03/ 0.00 0.07 1.21/ 0.004
MMP-3 (ng/ml) 0.20 6.18/ 0.00 0.15 2.42/ 0.00 0.12 3.80/ 0.00
MMP-9 (ng/ml) 9.84 109.78/ 2.16 9.84 91.03/ 0.30 9.84** 55.06/ 0.63
MMP-13 (ng/ml) 0.41 38.44/ 0.05 0.22 10.93/ 0.02 0.22 59.92/ 0.03
Minocycline group (N=19)
Baseline 1 month 3 months
median max/ min median max/ min median max/ min
IL-1a (ng/ml) 3.57 11.01/ 0.04 3.77 13.50/ 0.05 5.22 12.63/ 0.11
IL-1b (ng/ml) 0.04 0.24/ 0.00 0.03 0.40/ 0.00 0.05 0.62/ 0.00
IL-6 (pg/ml) 0.00 19.56/ 0.00 0.00 8.65/ 0.00 0.00 4.49/ 0.00
IL-8 (ng/ml) 0.16 14.49/ 0.01 0.13 2.50/ 0.002 0.29 1.13/ 0.02
TNF-a (pg/ml) 2.95* 11.14/ 0.76 3.43 18.25/ 0.00 4.91 36.79/ 0.37
CRP (ng/ml) 0.32 0.45/ 0.11 0.27 0.48/ 0.11 0.28 0.41/ 0.11
MMP-1(ng/ml) 0.03 0.87/ 0.007 0.04 0.72/ 0.00 0.03 0.42/ 0.005
MMP-3 (ng/ml) 0.17 3.96/ 0.00 0.12 0.96/ 0.00 0.08 3.62/ 0.00
MMP-9 (ng/ml) 20.96 142.31/ 0.13 16.34 229.63/ 0.88 19.21** 114.21/ 0.39
MMP-13 (ng/ml) 0.20 2.17/ 0.04 0.22 2.36/ 0.02 0.12 3.48/ 0.003
Table 3: Biochemical markers in peri-implant crevicular fluid at peri-implant diseases in each group.
*Significantly higher in laser group compared to tetracycline group at baseline (P=0.004).
**Significantly lower in laser group compared to tetracycline group at 3 months (P=0.009).
range of the assay were used for undetectable biomarkers 
that fell below or above the lower and upper limits of the 
assay, respectively. Data regarding the 10 biochemical 
markers in PICF are summarized in Table 3.
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At baseline, all biochemical markers analyzed in this 
study were comparable between the EYL and the MC 
groups (p > 0.05), with the exception of TNFα, which 
was significantly greater in the EYL group (p = 0.004). 
Intragroup comparisons revealed no significant differen-
ces in any of the biochemical markers at 1 and 3 mon-
ths after treatment, as compared with baseline values in 
both groups (p> 0.05). In addition, intergroup compa-
risons revealed significantly lower levels of MMP-9 in 
the EYL group than in the MC group at 3 months after 
treatment (p = 0.009).
Discussion
Our results showed that non-surgical EYL treatment for 
PID was clinically effective in reducing PPD. In addi-
tion, significantly lower levels of MMP-9 in PICF were 
observed at 3 months after treatment in EYL treatment 
compared to MC treatment.
The clinical effectiveness of non-surgical EYL treatment 
on PI has already been summarized in review articles 
(13,15). In the present study, the EYL energy level was 
set at 30 mJ/ 25 pps (panel setting), as recommended in 
a previous study (14), in which a tip-end power of 100 
mJ/mm2 was able to remove contaminated debris and 
titanium oxide from the implant surface without causing 
any surface alterations or heating side effects. This tip-
end power of 100 mJ/mm2 is equivalent to about 30 mJ 
at the panel setting, when the PS600T chip was used.
Regarding microbiota, analysis of the synergistic and 
dysbiotic microbial community rather than specific pe-
riodontal microbiota is reported to be essential to clarify 
the pathogenesis of periodontitis (19). Like periodon-
titis, comprehensive analysis should be important for 
the microbiota in peri-implant pocket with PID; there-
fore, the composition of bacterial flora in each infected 
implant was evaluated, and changes in bacterial flora 
composition as well as the reduction in bacterial counts 
between the two treatments modalities were compared. 
The results suggested that the species of the detected 
bacteria varied among individuals rather than disease 
status, and none of the bacteria were specifically asso-
ciated with PID (data not shown).
Non-surgical EYL treatment for PID did not lead to a 
significant reduction in bacterial counts when compa-
red to baseline observation in both PCR-invader and 
T-RFLP analysis. The results may be due to the low bac-
terial counts at baseline and the limited approach of the 
non-surgical EYL closed treatment. On the other hand, 
in the MC group, the counts of almost all bacterial spe-
cies were significantly lower after treatment. This diffe-
rence could be explained by the observation that EYL 
irradiation was performed for 5 min at baseline, and the 
laser energy (two-thirds) in the PS600T tip was directed 
forward in the peri-implant pocket. Therefore, the short 
duration of EYL irradiation might have had a limited 
effect on the implant surface. This incomplete disinfec-
tion of non-surgical EYL treatment was also reported in 
another study (20). In vitro, however, the strong bacteri-
cidal effects of EYL on periodontopathic bacteria have 
already been proven (21); therefore, clinical use of EYL 
could have some benefits in preventing or minimizing 
bacteremia, bacterial resistance and microbial substitu-
tion. Further studies regarding the timing and duration 
of laser irradiation using a newly developed laser chip, 
and comparison with open-flap surgical treatment are 
needed to elucidate the capabilities of EYL.
Multiplex bead immunoassay successfully identified va-
rious markers associated with PID, even from very limited 
sample. As shown in table 3, the EYL group showed sig-
nificantly lower MMP-9 levels, as compared with the MC 
group at 3 months after treatment. Among MMPs, neu-
trophil-derived MMPs (MMP-8 and MMP-9) have been 
reported to play major roles in tissue destruction in perio-
dontitis (22-24). It was also suggested that the MMP-mo-
nitoring in gingival clevicular fluid (GCF) proved to be 
a useful tool in understanding disease progression (23). 
The MMP-9 in GCF was produced by polymorphonu-
clear leukocytes (PMN) (22). Not only PMN but also 
macrophages, keratinocytes and osteoclasts are reported 
to express MMP-9 in periodontitis lesions (25,26). Ma et 
al. analyzed MMP-9 levels in PICF and concluded their 
association with peri-implant BL (27). Özçakır-Tomruk et 
al. also reported that relative MMP-9 activity was increa-
sed in PI when compared with peri-implant mucositis or 
healthy controls, and was significantly related to increase 
PPD, which is a sign of BL around implants (28). The 
results of the present study in clinical and biochemical 
analysis in PICF were supported by these reports. 
The aforementioned reports were comparative studies 
between PID and healthy implants or natural teeth. To 
the best of our knowledge, the present study is the first 
to evaluate changes in MMP-9 levels in PICF after PID 
treatment. EYL irradiation may have some effects on 
host cells, including PMN function with biological res-
ponse through decreased levels of MMP-9, which could 
lead to decreased peri-implant tissue destruction. Howe-
ver, it should be noted that MMP-9 levels in PICF in the 
present study showed a wide range in individuals and 
could not be partially quantified when overexpressed. 
In conclusion, within the limitations of the present study, 
non-surgical treatment with an EYL for PID was clini-
cally effective and may associated with reducing pe-
ri-implant tissue destruction through decreased MMP-9 
levels in PICF. Further investigations involving a longer 
term and larger sample size, as well as surgical treatment 
by EYL are needed.
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